The global fecal calprotectin test market is estimated to be valued at US$ 161.98 Mn in 2024 and is expected to exhibit a CAGR of 3.9% over the forecast period 2024 to 2030.
Fecal calprotectin tests are non-invasive screening tests used to detect inflammatory bowel disease (IBD) in patients experiencing gastrointestinal symptoms. Calprotectin is a protein found in the cytoplasm of neutrophils that is released during inflammation. When inflammation occurs in the bowel, calprotectin filters into the feces. A fecal calprotectin test measures the level of calprotectin in a stool sample to determine inflammation in the digestive tract. The test is used to screen and diagnose IBD, monitor patient response to treatment, and detect relapse. The market is driven by the rising prevalence of IBD, growth in disease screening, and advantages such as non-invasive nature and high sensitivity and specificity of fecal calprotectin tests over traditional diagnostic techniques.
Key Takeaways
Key players operating in the fecal calprotectin test market are John Deere, Vermeer Corporation, Kuhn Group, AGCO Corporation, Krone North America, New Holland Agriculture, Claas Group, Kubota Corporation, Fella Maschinenbau GmbH, Sitrex S.p.A., Deutz-Fahr, Enorossi, Tonutti, Galfre, Pottinger Agricultural Machinery. The key players are focusing on new product launches, partnerships and acquisitions to strengthen their market position and expand their geographical presence. The increasing awareness and adoption of screening for IBD and other digestive diseases is boosting the demand for fecal calprotectin testing. Furthermore, technological advancements such as development of rapid and home-based sampling and testing solutions are expected to drive the market growth during the forecast period.
Market Trends
The fecal calprotectin test market is witnessing the trend of rapid tests and home-based sample collection kits. Companies are developing rapid calprotectin tests that can provide results within 15 minutes to facilitate point-of-care testing. Home-based sampling kits are gaining traction as they offer convenience to patients for sample collection without visiting laboratories. The kits are integrated with collection vials and simple instructions for collection and shipping of samples back to laboratories.
Market Opportunities
Developing economies such as India, Brazil, China and Africa are expected to present significant opportunities owing to growing healthcare investments, rising awareness, and expanding medical reimbursements. There is increasing focus on screening programs for IBD in these regions which will drive testing rates. Growing geriatric population worldwide also presents opportunities due to higher vulnerability of older adults to digestive illnesses. Companies can focus on partnerships with healthcare providers and payers to facilitate adoption of fecal calprotectin testing and tap into the emerging opportunities.
Impact of COVID-19 on Fecal Calprotectin Test Market growth
The COVID-19 pandemic has negatively impacted the Fecal Calprotectin Test Market Growth. During the initial months of the outbreak, there was a decline in the number of non-emergency medical procedures and tests. This resulted in a reduced demand for fecal calprotectin tests as they are primarily used for screening and monitoring of inflammatory bowel diseases. Manufacturing and supply chain disruptions due to lockdowns further hampered market growth. However, as restrictions eased, the demand started recovering. Now, there is an increased focus on preventive healthcare and screening of chronic conditions like IBD. Market players are launching advanced home testing kits to meet the growing demand and make testing more accessible. Telehealth and virtual consultations are also helping in the management of IBD patients during the pandemic. In the coming years, the post pandemic rise in health awareness and focus on managing co-morbidities is expected to drive higher adoption of fecal calprotectin tests, pushing the market towards its pre-COVID growth trajectory.
Europe accounts for the largest share in the Fecal Calprotectin Test market in terms of value. Countries like Germany, U.K and Italy have high disease prevalence and reimbursement policies supporting routine screening and diagnosis of IBD using fecal calprotectin tests. The Asia Pacific region is poised to witness the fastest growth during the forecast period attributed to increasing disposable incomes, growing awareness about gastrointestinal disorders and expanding healthcare infrastructure in developing nations. China and India are emerging as lucrative markets. North America will also grow steadily due to established patient population, favorable insurance coverage and rising trend of home healthcare.
North American Fecal Calprotectin Test Market
The North American region holds a significant share in the global fecal calprotectin test market owing to supportive reimbursement policies and aggressive marketing strategies by key players. In the United States, inflammatory bowel diseases (IBD) have a high prevalence rate of over 3 million people. This established patient base and inclusion of fecal calprotectin tests in diagnostic guidelines are driving higher adoption. Reimbursement for fecal calprotectin tests by Medicare, Medicaid and private payers makes it affordable for patients. Players are introducing advanced rapid home testing kits with clear instructions to expand accessibility. Companies also conduct extensive awareness campaigns through patient advocacy groups in the country. The demand is further supplemented by growing focus on personalized medicine approach for IBD management. Canada follows similar trends regarding disease burden, availability of treatments and regulatory policies. Overall, the North American market is expected to show steady growth over the forecast years.
Get more insights on Fecal Calprotectin Test Market
